EFFICIENCY OF USING THE PROBIOTIC «LACTIALE GERMINA FORTE» IN THE COMPLEX TREATMENT OF PATIENTS WITH COVID-19
DOI:
https://doi.org/10.11603/1681-2727.2023.2.14098Keywords:
COVID-19, intestinal microflora, pro-inflammatory cytokines, probiotic, Bacillus clausii UBBC-07Abstract
SUMMARY. The purpose of the work is to analyze the frequency and spectrum of disorders of the digestive tract in patients with COVID-19 and to evaluate the effectiveness of the use of a probiotic containing B. clausii UBBC-07 spores.
Materials and methods. 85 patients with COVID-19 were examined, of which 59 (69.4 %) had gastrointestinal disorders. They were divided into two groups: group I included 30 (50.9 %) patients who, in addition to standard therapy, were prescribed the probiotic «Lactiale Germina Forte» 1 bottle 2 times a day for 7 days, group II – 29 (49.1 %) of patients who received standard etiotropic and pathogenetic therapy.
Research results. Gastrointestinal disorders in patients with COVID-19 were characterized by decreased or absent appetite, diarrhea, bitterness in the mouth, abdominal pain, nausea, vomiting. Symptoms of TC damage on the 7th day from the start of treatment persisted in 5 (16.7 %) patients of group I and 20 (69.0 %) of patients from group II (р˂0.001). In the representatives of group I, the content of interleukin-1β, interleukin-2, and interleukin-8 decreased dynamically compared to the initial level (р˂0.01), and was lower than the similar indicator in the comparison group (р˂0.05) after treatment. Also, in these patients, there was an increase in the content of bifidobacteria and lactobacilli relative to the significantly reduced initial level (р˂0.001), inhibition of the growth of Staphylococcus aureus (р˂0.001), fungi of the genus Candida (р˂0.01), a decrease in the number of Escherichia coli with reduced enzymatic activity activity (р˂0.001), enterococci (р˂0.001), a tendency to decrease the number of Escherichia coli with hemolytic activity (р˃0.05).
Conclusions. The emergence of digestive tract disorders is typical for COVID-19. The use of «Lactiale Germina Forte» in the complex therapy of patients contributes to the regression of clinical manifestations, normalization or approximation to normalization of the content of pro-inflammatory cytokines in the blood serum, restoration of the state of the intestinal microflora, compared to standard therapy.
References
Kumar, A., Arora, A., Sharma, P., Anikhindi, S. A., Bansal, N., Singla, V., Khare, S., & Srivastava, A. (2020). Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis. Indian Journal Gastroenterology, 39(3), 268-284. DOI: 10.1007/s12664-020-01058-3.
Mao, R., Qiu, Y., He, J. S., Tan, J. Y., Li, X. H., Liang, J., … & Chen, M. H. (2020). Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 5(7), 667-678. DOI: 10.1016/S2468-1253(20)30126-6.
Elshazli, R. M., Kline, A., Elgaml A., Aboutaleb, M. H., Salim, M. M., Omar, M., … & Kandil, E. (2021). Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves. J. Med. Virol., 93 (5), 2740-2768. DOI: 10.1002/jmv.26836.
Yong, S. J. (2021). Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond), 53(10), 737-754. DOI: 10.1080/23744235.2021.1924397.
Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C., Sepulveda, R., Rebolledo, P. A., Cuapio, A., & Villapol S. (2021). More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. MedRxiv. https://www.medrxiv.org. DOI: 10.1101/2021.01.27.21250617.
Salabei, J. K., Fishman, T. J., Asnake, Z. T., Ali, A., & Iyer, U. G. (2021). COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Heart Lung, 50 (2), 357-360. DOI: 10.1016/j.hrtlng.2021.01.011.
Deidda, S., Tora, L., Firinu, D., Giacco, S. D., Campagna, M., Meloni, F., … & Restivo, A. (2021). Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management. Expert Rev. Gastroenterol. Hepatol., 15 (1), 41-50. DOI: 10.1080/17474124.2020.1821653.
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., … & Li, J. Z. (2020). Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. New England Journal of Medicine, 383 (23), 2291-2293. DOI: 10.1056/NEJMc2031364.
Hu, F., Chen, F., Ou, Z., Fan, Q., Tan, X., Wang, Y., … & Li, F. (2020). A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cell. & Mol. Immunol., 17, 1119-1125. DOI: 10.1038/s41423-020-00550-2.
Kumar, V. (2021). How could we forget immunometabolism in SARS-CoV2 infection or COVID-19? Int. Rev. Immunol., 4 0(1-2), 72-107. DOI: 10.1080/08830185.2020.1840567.
de Castro, J. A., Guno, M. J. V., & Perez, M. O. (2019). Bacillus clausii as adjunctive treatment for acute community-acquired diarrhea among Filipino children: a large-scale, multicenter, open-label study (CODDLE). Trop. Dis. Travel Med. Vaccines, 23, 5-14. DOI: 10.1186/s40794-019-0089-5. PMID: 31367461; PMCID: PMC6651909.
Lahiri, K. R., Singh, R., Apte, M., Patil, M., Taksande, A., Varona, R., … & Perez, M. I. (2022). Efficacy and safety of Bacillus clausii (O/C, N/R, SIN, T) probiotic combined with oral rehydration therapy (ORT) and zinc in acute diarrhea in children: a randomized, double-blind, placebo-controlled study in India. Trop. Dis. Travel Med. Vaccines, 8 (9). DOI: 10.1186/s40794-022-00166-6.
Sudha, M. R., Jayanthi, N., Pandey, D. C., & Verma, A. K. (2019). Bacillus clausii UBBC-07 reduces severity of diarrhoea in children under 5 years of age: a double blind placebo controlled study. Benef. Microbes, 10 (2), 149-154. DOI: 10.3920/BM2018.0094.
Madempudi, R. S., Neelamraju, J., Ahire, J. J., Muthukumar, M., Rudrappa, S., Gopal, G., & Nagendra, K. (2022). Bacillus clausii UBBC-07 in the symptom management of upper respiratory tract infections in children: a double blind, placebo-controlled randomised study. Benef. Microbes, 13(4), 331-339. DOI: 10.3920/BM2021.0187.
Rea, K., Colom, J., Simon, E. A., Khokhlova, E., Mazhar, S., Barrena, M., … & Deaton, J. (2023). Evaluation of Bacillus clausii CSI08, Bacillus megaterium MIT411 and a Bacillus cocktail on gastrointestinal health: a randomised, double-blind, placebo-controlled pilot study. Benef. Microbes, 14(2), 165-182. DOI: 10.3920/BM2022.0117.
Vázquez-Frias, R., Consuelo-Sánchez, A., Acosta-Rodríguez-Bueno, C. P., Blanco-Montero, A., Robles, D. C., Cohen, V., Márquez, D., & Perez, M. 3rd. (2023). Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study. Paediatr. Drugs, 25(1), 115-126. DOI: 10.1007/s40272-022-00536-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 K. V. Yurko, H. O. Solomennyk, V. V. Kucheryavchenko
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
